Target Name: CCKBR
NCBI ID: G887
Review Report on CCKBR Target / Biomarker Content of Review Report on CCKBR Target / Biomarker
CCKBR
Other Name(s): Gastrin receptor | Gastrin/cholecystokinin type B receptor (isoform 1) | CCK2 | Cholecystokinin B receptor, transcript variant 1 | Cholecystokinin-2 receptor | CCK2-R | CCK-BR | CCKRB | CCK2 (CCKB/Gastrin) receptor (CCK-BR; CCK2-R) | Cholecystokinin B receptor | gastrin receptor | CCKBR variant 1 | GASR | CCK-B receptor | hGARE | cholecystokinin B receptor | CCK-B | Gastrin/cholecystokinin type B receptor | CCK2R | cholecystokinin-2 receptor | GASR_HUMAN | CCK2 receptor

CCKBR: A 鈥嬧?婸otential Drug Target and Biomarker for Gastrin Receptor-Positive Cancers

Introduction

Gastrin, a hormone produced by the stomach, plays a crucial role in the digestive process. It is a 26-kDa protein that consists of two subunits, subunit A (44 amino acids) and subunit B (42 amino acids). The subunit A region of gastrin contains the catalytic active site, which is responsible for the hormone's digestive function. Gastrin receptor (GR), a transmembrane protein that belongs to the G-protein-coupled receptor (GPCR) family, is the protein target of CCKBR, a potential drug target and biomarker for gastrin receptor-positive cancers. This article will discuss the biology of CCKBR, its potential as a drug target, and its potential as a biomarker for gastrin receptor-positive cancers.

Biography of CCKBR

CCKBR, also known as Gastrin Receptor-B, is a 198-amino acid protein that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. It is a member of the GPCR family and is characterized by the presence of a nucleotide-binding oligomerization domain (NBD), a characteristic of GPCR family proteins. CCKBR functions as a receptor for the neurotransmitter gastrin, which is produced by the stomach.

CCKBR is a critical regulator of several physiological processes in the body, including cell growth, differentiation, and survival. It is involved in the regulation of neurotransmitter signaling, stem cell proliferation, and cancer growth. In addition, CCKBR is also involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed.

Potential as a Drug Target

The potential of CCKBR as a drug target is based on its involvement in several cellular processes that are associated with cancer development. CCKBR has been shown to play a role in the regulation of angiogenesis, which is a critical process for the development and progression of cancer . In addition, CCKBR has also been shown to be involved in the regulation of neurotransmitter signaling, which is critical for the regulation of cellular processes that are associated with cancer growth.

One of the most promising strategies for targeting CCKBR is the use of small molecules that can modulate its activity. Small molecules that can modulate CCKBR activity have been shown to be effective in several preclinical studies for the treatment of several types of cancer, including breast, ovarian, and colorectal cancers. These small molecules include, but are not limited to, tyrosine kinases, inhibitors of protein tyrosine phosphatases, and inhibitors of DNA binding proteins.

Potential as a Biomarker

CCKBR has also been shown to be a potential biomarker for several types of cancer, including gastrin receptor-positive cancers. Gastrin receptor-positive cancers, also known as G-protein-coupled receptor (GR) positive cancers, are a subtype of cancer that are characterized by the presence of the GR protein on the surface of the cancer cell. These cancers are associated with poor prognosis and treatment outcomes because of their high sensitivity to chemotherapy and radiation therapy.

However, the use of CCKBR as a biomarker for gastrin receptor-positive cancers has been shown to be promising. Studies have shown that CCKBR levels are significantly increased in the brains and other tissues of patients with gastrin receptor-positive cancers, compared to the levels in healthy tissue. Additionally, several studies have shown that the levels of CCKBR are significantly increased in the tumors of patients with gastrin receptor-positive cancers, compared to the levels in the surrounding tissue.

Conclusion

In conclusion, CCKBR is a protein that is involved in several physiological processes in the body, including cell growth, differentiation, and survival. It is also a critical regulator of several cellular processes that are associated with cancer development, including the regulation of angiogenesis and neurotransmitter signaling. The potential of CCKBR as a drug target and biomarker for gastrin receptor-positive cancers is based on its involvement in these processes. Further research is needed to fully understand the role of CCKBR

Protein Name: Cholecystokinin B Receptor

Functions: Receptor for gastrin and cholecystokinin. The CCK-B receptors occur throughout the central nervous system where they modulate anxiety, analgesia, arousal, and neuroleptic activity. This receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system

The "CCKBR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCKBR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCL1 | CCL11 | CCL13 | CCL14 | CCL15 | CCL15-CCL14 | CCL16 | CCL17 | CCL18 | CCL19 | CCL2 | CCL20 | CCL21 | CCL22 | CCL23 | CCL24 | CCL25 | CCL26 | CCL27 | CCL28 | CCL3 | CCL3-AS1 | CCL3L1 | CCL3L3 | CCL3P1 | CCL4 | CCL4L1 | CCL4L2 | CCL5 | CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5